

30. (Twice Amended) [The] A vaccine composition [of claim 26] comprising at least one antigen and [wherein said amphipathic adjuvant compound is selected from the group consisting of: cholesteryl-3-E-carboxyamidoethylenetriethylammonium iodide, cholesteryl-3-E-carboxyamidoethylenamine, cholesteryl-3-E-oxysuccinamidoethylene-trimethylammonium iodide,] 3-E-(N-(N-N'-dimethylaminoethane)carbamoyl) cholesterol [, and 3-E-(N-(N-N'-polyethylenamine)carbamoyl) cholesterol].

33. (Twice Amended) The vaccine composition of claim [25] 30, further comprising a neutral lipid.

36. (Twice Amended) The vaccine composition of claim [25] 30, wherein said [amphipathic adjuvant compound] 3-E-(N-(N-N'-dimethylaminoethane)carbamoyl) cholesterol is dispersed in an aqueous environment in the form of liposomes.

37. (Twice Amended) The vaccine composition of claim [25] 30, wherein said 3-E-(N-(N-N'-dimethylaminoethane)carbamoyl) cholesterol [amphipathic adjuvant compound] takes the form of liposomes including at least one antigen.

62. (Twice Amended) A method of inducing an immune response in a mammal, comprising administering the vaccine composition of claim [25] 30, to a mammal.

75. (Twice Amended) A method of inducing an immune response in a mammal, comprising

- (a) administering at least one antigen to a mammal; and

(b) further administering [at least one amphipathic adjuvant compound comprising a lipophilic group derived from a sterol linked to a polar group via a carbamoyl group] the vaccine composition of claim 30, to a mammal.

In the specification:

Please insert --Brief Description of the Drawings-- at page 6, between lines 20 and 21.

Please delete Tables 1 and 2 at page 12.

Please insert --Figure 17 depicts the results mentioned in Example 9.-- at page 7, between lines 8 and 9.

Please insert --Figure 18 depicts the results mentioned in Example 9.-- at page 7, between lines 9 and 10.

At line 11, line 17, please delete "Table 1" and insert therefor --Figure 17--.

At line 11, line 18, please delete "Table 2" and insert therefor --Figure 18--.

In the drawings:

Please add Figures 17 and 18.

REMARKS

The Examiner indicated that claims 25-88 were pending at the issuance of the instant Office Action. Claims 25-27, 29, 38-60, and 70-74 have been cancelled without prejudice in this response and claims 28, 30, 33, 36, 37, 62, and 75 have been amended. Support for these amendments can be found within the specification as originally filed at, for example, page 2, lines 14-17 and at page 2, line 25 to page 3, line 4. No new matter has been added as a result of